Tesamorelin Research Information
Growth Hormone-Releasing Factor (GHRF) Analog
For Metabolic & Visceral Fat Research
️ Important: This information is for educational and research purposes only. Always consult with a qualified healthcare professional before use.
Contents
What is Tesamorelin?
Tesamorelin is a synthetic 44-amino acid peptide analog of human Growth Hormone-Releasing Factor (GRF) that acts as a potent agonist at the GHRH receptor on pituitary somatotroph cells, stimulating the synthesis and pulsatile release of endogenous growth hormone (GH). It is the first and only FDA-approved treatment indicated for the reduction of excess abdominal fat in HIV-associated lipodystrophy.
Tesamorelin binds and stimulates human GRF receptors with similar potency as the endogenous GRF. It restores the body's natural pulsatile GH release pattern, offering a more physiological approach compared to exogenous GH administration. Tesamorelin is available in pen and freeze-dried vial formulations for research purposes.
How Tesamorelin Works
Tesamorelin works through a targeted mechanism to stimulate natural growth hormone release:
GHRH Receptor Binding
Binds to GHRH receptors on pituitary somatotroph cells with potency similar to endogenous GRF
Endogenous GH Release
Stimulates pituitary to release natural growth hormone in a pulsatile pattern
Metabolic Effects
GH exerts lipolytic and anabolic effects via IGF-1 on target cells including adipocytes and hepatocytes
Tesamorelin restores pulsatile GH secretion and thereby offers a more physiological means of reducing visceral adipose tissue. The effects are primarily mediated by IGF-1 produced in the liver and in peripheral tissues.
Research Applications
Visceral Fat Reduction
FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy
Liver Fat Research
Significant reduction in hepatic fat fraction in clinical trials
Body Composition
Increases lean body mass while reducing trunk fat
Metabolic Research
Studying effects on glucose homeostasis and metabolic health
Clinical Studies
Meta-Analysis of Randomized Controlled Trials (ScienceDirect 2026)
- Five RCTs showed Tesamorelin significantly reduced visceral adipose tissue (MD: −27.71 cm², 95% CI [−38.37, −17.06]; P < 0.001)
- Trunk fat reduction: MD: −1.18 kg, 95% CI [−1.40, −0.96]; P < 0.001
- Hepatic fat percentage reduction: MD: −4.28%, 95% CI [−6.31, −2.24]; P < 0.001
- Lean body mass increase: MD: 1.42 kg, 95% CI [1.13, 1.71]; P < 0.001
- Waist circumference reduction: MD: −1.61 cm, 95% CI [−2.28, −0.95]; P < 0.001
- No significant changes in CD4+ T-cell counts
- Adverse events included arthralgia, myalgia, paresthesia, and injection-site reactions
HIV-Associated Lipodystrophy in INSTI Users (AIDS 2024)
- First dedicated data on Tesamorelin efficacy and safety among people with HIV on integrase inhibitor (INSTI)-based regimens
- Visceral fat decline: median −25 cm² vs +14 cm² with placebo (P = 0.001)
- Hepatic fat reduction: −4.2% vs −0.5% with placebo (P = 0.01)
- Trunk-to-appendicular fat ratio reduction: −0.1 vs 0.0 with placebo (P = 0.03)
- Well tolerated with similar frequency of adverse events, including hyperglycemia, between groups
FDA-Approved Dosing (EGRIFTA SV)
- FDA-approved dose: 1.4 mg (0.35 mL of reconstituted solution) injected subcutaneously once daily
- Reconstitute one vial of 2 mg lyophilized powder with 0.5 mL of diluent
- Administer immediately following reconstitution; discard any unused solution
- Not indicated for weight loss management; weight neutral effect
- Long-term cardiovascular safety has not been established
Pharmacokinetics
- Absolute bioavailability is low (< 4%)
- Elimination half-life is rapid, estimated at 0.3-0.6 hours
- Inter-individual variability is high, especially for AUC
- Volume of distribution: 10.48 to 20.19 L/kg
Interactive Dosing Guide
Select your vial size and dose to see the corresponding volume, clicks, dosing frequency, and how many doses per vial:
️ Step 1: Select Your Vial Size
Step 2: Select Your Dose
Common research protocols: 0.1-0.5 mg per injection, typically 1.4 mg FDA-approved dose
Vial Size
2mg Vial
Selected Dose
0.1 mg
Doses per Vial
20 doses
Pen Clicks
15 clicks
Volume
0.15 mL
Protocol Level
Level 1 (Starting)
Recommended Schedule
Once daily - Loading Phase
️ Do not change your dose unless advised by a qualified professional.
Protocol Level Summary
Based on research protocols: 0.1-0.5 mg per injection, typically administered once daily. FDA-approved dose is 1.4 mg.
| Protocol Level | Target Dose | Frequency | 2mg Clicks | 5mg Clicks | 10mg Clicks | Who It\'s For |
|---|---|---|---|---|---|---|
| Level 1 (Starting) | 0.1 mg | Once daily | 15 clicks | 6 clicks | 3 clicks | New users, first 2 weeks |
| Level 2 (Standard) | 0.2 mg | Once daily | 30 clicks | 12 clicks | 6 clicks | After 2 weeks, maintenance |
| Level 3 (Advanced) | 0.3-0.4 mg | Once daily | 45-60 clicks | 18-24 clicks | 9-12 clicks | If more response needed |
| Level 4 (Maximum) | 0.5 mg | Once daily | 75 clicks | 30 clicks | 15 clicks | Experienced users only |
️ Do not change your dose unless advised by a qualified professional.
Vial Users (Insulin Syringe)
Add 3mL of bacteriostatic water to your freeze-dried vial and mix gently. After reconstitution, use the table below to draw your dose:
Vial Size
2mg vial with 3mL bac water
| Dose | Frequency | Units on Syringe | Volume (mL) | Protocol Level |
|---|
️ Always use a new sterile needle and syringe for each injection.
️ Safety & Precautions
Tesamorelin has been studied in clinical trials with a manageable safety profile. The most common adverse events in meta-analyses included arthralgia, myalgia, paresthesia, and injection-site reactions like erythema.
- Injection site reactions: Erythema, pain, or tenderness at injection site
- Arthralgia: Joint pain, commonly reported
- Myalgia: Muscle pain
- Paresthesia: Tingling or numbness
- Hyperglycemia: Similar frequency between tesamorelin and placebo groups
Important Safety Considerations:
- FDA-approved for reduction of excess abdominal fat in HIV-associated lipodystrophy
- Not indicated for weight loss management – weight neutral effect
- Long-term cardiovascular safety has not been established
- Do not use if allergic to tesamorelin or any ingredients
- Do not use if pregnant or breastfeeding
️ Warning: Tesamorelin is a growth hormone-releasing factor analog with FDA approval for a specific indication. If you experience severe allergic reactions, difficulty breathing, or signs of anaphylaxis, seek immediate medical help.
References
- Russo SC, Ockene MW, Arpante AK, et al. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors. AIDS. 2024;38(12):1758-1764.
- DailyMed - EGRIFTA SV (tesamorelin) FDA Labeling. Updated December 2025.
- NCATS Inxight Drugs - Tesamorelin. Inxight Drugs.
- EMA Withdrawal Assessment Report - Egrifta.
- Badran AS, Helal A, Ayesh H, et al. Body composition, hepatic fat, metabolic, and safety outcomes of Tesamorelin in HIV-associated lipodystrophy: A meta-analysis of randomized controlled trials. ScienceDirect. 2026.
- Pharos - Tesamorelin. Illuminating the Druggable Genome.
This information is for educational and research purposes only. Always consult with a qualified healthcare professional.
Last updated: July 2026